breast cancer

[Scientific Reports] A patient-derived scaffold model was evaluated as a testing platform for the endocrine therapies (Z)-4-Hydroxytamoxifen and fulvestrant as well as the CDK4/6-inhibitor palbociclib, monitoring the treatment responses in breast cancer cell lines MCF7 and T47D adapted to the patient-based microenvironments.

[Life Sciences] The authors summarize the current knowledge on the cardiac signaling pathways modulated by two antineoplastic drugs highly used in the management of breast cancer, not only focusing on cardiomyocytes but also to broaden the knowledge of the potential impact on other cells found in the heart.

[npj Breast Cancer] Using a novel approach in estrogen receptor-positive (ER+) and negative breast cancer, researchers identified perinuclear-localized expression of STING in ER+ cases as an independent predictor of good prognosis, associated with immune cell infiltration and upregulation of immune checkpoints.

[Nature] Researchers generated 42,000 genomes from multi-year time-series single-cell whole-genome sequencing of breast epithelium and primary TNBC patient-derived xenografts, revealing the nature of copy number alteration-defined clonal fitness dynamics induced by TP53 mutation and cisplatin chemotherapy.

[Communications Biology] Scientists indicated that CSCs may enjoy blood perfusion to maintain their stemness features. Targeting the lysophosphatidic acid/protein kinase D -CD36 signaling pathway may have therapeutic potential to curb tumor progression by disrupting the arteriolar niche and effectively eliminating CSCs.

[HUYABIO InternationalTM (PR Newswire, Inc.)] HUYABIO International™ announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency. The drug was approved based on data from a Phase IIb study that involved 23 patients with aggressive ATL in Japan.